What are the common and serious side effects of capecitabine (Xeloda) chemotherapy and how should they be managed?

Capecitabine Chemotherapy Side Effects and Management

Capecitabine causes predictable dose-dependent toxicities that require immediate recognition and dose modification to prevent life-threatening complications, with hand-foot syndrome, diarrhea, and gastrointestinal toxicity being the most common adverse effects. 1

Common Side Effects

Gastrointestinal Toxicity

The most frequent adverse effects include:

• Diarrhea (often severe)
• Nausea and vomiting
• Stomatitis (mouth sores)
• Abdominal pain
• Loss of appetite
• Dehydration (particularly in patients ≥80 years) 1

Hand-Foot Syndrome (Palmar-Plantar Erythrodysesthesia)

This is the signature toxicity of capecitabine, occurring significantly more frequently than with IV 5-FU 2, 3:

• Presents as tingling, numbness, pain, swelling, or redness of palms and soles
• Incidence: 73.4% all grades, 11.1% grade 3 in clinical trials 3
• More common in North American patients compared to other populations 2
• Interestingly, development of hand-foot syndrome correlates with improved survival 2

Hematologic Effects

• Neutropenia (6.3% grade 3/4) 3
• Lymphopenia and anemia 4
• Significantly less myelosuppression compared to IV 5-FU regimens 5, 4

Other Common Effects

• Fatigue and weakness
• Dermatologic: rash, dry/itchy skin, nail problems
• Hair loss (less common than with IV 5-FU)
• Hyperbilirubinemia 6

Serious and Life-Threatening Side Effects

Dihydropyrimidine Dehydrogenase (DPD) Deficiency Syndrome

This is a potentially fatal complication that occurs in 3-5% of the population 7:

• Presents with severe bone marrow suppression, severe diarrhea, mucositis, and hair loss
• Absolute contraindication: Known DPD deficiency 1
• Management approach:
  • If heterozygous mutation: 50% dose reduction for first cycle, then increase as tolerated
  • If homozygous mutation: Consider whether capecitabine can be safely administered at all
  • Even patients without identified mutations can rarely present with this syndrome 7

Severe Diarrhea and Enterocolitis

Stop capecitabine immediately if 1:

• ≥4 additional bowel movements per day beyond baseline
• Any nighttime diarrhea
• Signs of dehydration or sepsis

The rare capecitabine-induced enterocolitis can be life-threatening and requires immediate drug discontinuation 7.

Cardiovascular Toxicity

Patients with pre-existing heart disease may experience increased cardiac side effects 1.

Metabolic Complications

Rare but serious cases include:

• Severe hyperglycemia and diabetes 8
• Hypokalemia 8

Critical Management Algorithm

When to Stop Capecitabine Immediately 1

Contact physician and hold drug if any of the following occur:

1. Diarrhea: ≥4 additional bowel movements/day or any nighttime diarrhea
2. Vomiting: >1 episode in 24 hours
3. Nausea: Severe appetite loss with markedly reduced food intake
4. Stomatitis: Pain, redness, swelling, or sores in mouth
5. Hand-foot syndrome: Pain, swelling, or redness preventing normal activity
6. Fever/Infection: Temperature ≥100.5°F or signs of infection

Dose Modification Strategy 1

First occurrence of Grade 2 toxicity:

• Interrupt treatment until resolved to grade 0-1
• Resume at same dose during cycle
• If persisting at next cycle: delay until resolved, then continue at 100% dose

First occurrence of Grade 3 toxicity:

• Interrupt treatment until resolved to grade 0-1
• Resume at 75% of original dose
• Subsequent cycles: continue at 75% dose

Second occurrence of Grade 2 toxicity:

• Interrupt until resolved
• Resume at 75% of original dose

Second occurrence of Grade 3 toxicity:

• Interrupt until resolved
• Resume at 50% of original dose

Grade 4 toxicity:

• Discontinue treatment unless physician determines continuation at 50% dose is in patient's best interest

Special Population Considerations

Elderly patients (≥65 years):

• Start at 1000 mg/m² twice daily rather than 1250 mg/m² 3
• In North American patients ≥65 years, initial dosing at 1250 mg/m² caused 34% grade 3+ toxicity including 2 deaths, necessitating dose reduction 3

Renal impairment:

• CrCl 30-50 mL/min: 75% dose reduction required 1, 6
• CrCl <30 mL/min: Contraindicated 1, 6

Hepatic impairment:

• Monitor liver function during treatment 1

Critical Drug Interactions

Warfarin (Coumadin) 1

This is the most important drug interaction:

• Capecitabine significantly increases warfarin effect
• Requires frequent INR monitoring and warfarin dose adjustment
• Can lead to serious bleeding complications

Phenytoin (Dilantin) 1

• Capecitabine increases phenytoin levels
• Requires more frequent phenytoin level monitoring and dose adjustment

Folic Acid 1

• May affect capecitabine efficacy

Common Pitfalls to Avoid

1. Geographic dosing differences: North American patients experience higher toxicity rates than European or Asian patients at the same doses 2, 5

2. Age-related toxicity: Patients ≥80 years have significantly higher rates of gastrointestinal side effects 1

3. Delayed recognition: Most side effects improve within 2-3 days of stopping capecitabine if caught early 1

4. Inadequate patient education: Since capecitabine is oral home therapy, patients must understand when to stop the drug immediately 9

5. Dose escalation error: Once dose is reduced, never increase it again 1

6. Missed doses: If a dose is missed, do not double the next dose—continue regular schedule 1

Administration Guidelines 1

• Take within 30 minutes after meals (breakfast and dinner)
• Swallow with water
• Standard regimen: 14 days on, 7 days off (21-day cycles)
• Store at room temperature (65-85°F)

Contraindications 1

Absolute contraindications:

• Known DPD deficiency
• Allergy to capecitabine or 5-fluorouracil
• Pregnancy or breastfeeding
• CrCl <30 mL/min